RCS - C4X Discovery - Clive Dix awarded Honorary Fellowship

C4X Discovery HoldingsAnnouncement

02/12/2021 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211202:nRSB2999Ua&default-theme=true

RNS Number : 2999U  C4X Discovery Holdings PLC  02 December 2021

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Clive Dix awarded Honorary Fellowship by the British Pharmacological Society

 

2 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today announces that its Chief Executive Officer, Dr Clive
Dix BSc PhD HonFBPhS, has been awarded an Honorary Fellowship by the British
Pharmacological Society in recognition of sustained excellence and leadership
in science, healthcare, and public service.

 

Eva-Lotta Allan, Chairman of C4X Discovery, said: "The award of an Honorary
Fellowship by the prestigious British Pharmacological Society is testament to
Clive's accomplishments and the important work he continues to do for the
British healthcare industry and further afield.  As part of the team here at
C4XD, we are very proud to be working with Clive.  Throughout his career,
Clive has strived to promote British science at its best and this award shines
a light on the important contribution Clive has made.  Looking at the past
year alone, he served as Interim Chair of the UK Vaccines Taskforce, where he
was integral to the successful selection and roll-out of vaccines in the UK.
Under his leadership we also signed our second deal, this time with Sanofi for
total value up to €414 million. All of these achievements have only been
possible because of Clive's tireless determination to deliver life changing
medicines to patients in need, and we congratulate him on this well-deserved
Honorary Fellowship."

 

The British Pharmacological Society is a charity with a mission to promote and
advance the whole spectrum of pharmacology. It leads the way in the research
and application of pharmacology around the world, with members from more than
60 countries worldwide. Honorary Fellows are elected for life by the British
Pharmacological Society in recognition of sustained excellence and leadership
in science, healthcare, and public service. The Honorary Fellowship includes
Nobel Laureates, international prize-winners, long-standing members of the
Society, and those who have advanced the disciplines of Pharmacology, Clinical
Pharmacology and Therapeutics through research, leadership and contribution to
the British Pharmacological Society.

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977
 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRATBBTTMTMMTTB